Oxacillin sodium salt

Cat. No.:	HY-B0925	0
CAS No.:	1173-88-2	NaO
Molecular Formula:	$C_{19}H_{18}N_3NaO_5S$	N-10
Molecular Weight:	423.42	S S
Target:	Bacterial; Antibiotic	Ĥ H >
Pathway:	Anti-infection	N ^O
Storage:	4°C, sealed storage, away from moisture	
	* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)	\sim

SOLVENT & SOLUBILITY

Preparing Stock Solutio		Solvent Mass Concentration	1 mg	5 mg	10 mg	
	Preparing Stock Solutions	1 mM	2.3617 mL	11.8086 mL	23.6172 mL	
		5 mM	0.4723 mL	2.3617 mL	4.7234 mL	
		10 mM	0.2362 mL	1.1809 mL	2.3617 mL	
	Please refer to the sc	olubility information to select the app	propriate solvent.			
n Vivo		one by one: 10% DMSO >> 40% PEO ng/mL (5.90 mM); Clear solution	G300 >> 5% Tween-8	0 >> 45% saline		
		2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (5.90 mM); Clear solution				
		one by one: 10% DMSO >> 90% cor ng/mL (5.90 mM); Clear solution	m oil			

BIOLOGICAL ACTIVITY				
Description	Oxacillin sodium salt is an orally active synthetic penicillin with good bactericidal activity against staphylococci and other gram-positive pathogens ^[1] .			
IC ₅₀ & Target	β-lactam			
In Vitro	Oxacillin inhibits gram positive pathogens with MICs of 0.05, 0.09, 0.32 and 0.80 μg/mL against group A streptococci, Pneutnococci, susceptible staphylococci and penicillin-resistant staphylococci, respectively ^[1] . The Oxacillin-resistant strains are highly resistant to other penicillins ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.			



In Vivo	Evans. The oral CD_{50} of Oxa	Oxacillin (50-800 mg/kg; s.c.; once) shows curative dose (CD ₅₀) of 253.3 mg/kg in mice infected with Staphylococcus aureus Evans. The oral CD ₅₀ of Oxacillin is 187.2 mg/kg ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	Animal Model:	CD-1 strain male albino mice infected with S. aureus Evans ^[2]	
	Dosage:	50, 100, 200, 400 and 800 mg/kg	
	Administration:	Subcutaneous injection, once	
	Result:	Showed therapeutic activity with CD_{50} of 253.3 mg/kg.	

CUSTOMER VALIDATION

- Emerg Microbes Infect. 2024 Dec;13(1):2321981.
- iScience. 5 January 2022, 103731.
- Front Microbiol. 2020 Jul 31;11:1720.
- Microorganisms. 2024 Jan 25, 12(2), 256.
- BMC Microbiol. 2023 Apr 20;23(1):109.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. KIRBY WM, et al. Oxacillin: laboratory and clinical evaluation. JAMA. 1962 Sep 1;181:739-44.

[2]. Yurchenco JA, et al. Nafcillin and oxacillin: comparative antistaphylococcal activity in mice. J Antibiot (Tokyo). 1976 Apr;29(4):460-5.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA